Insmed (INSM) Stock Forecast & Price Target

$139.63 -0.38 (-0.27%)

As of 02:12 PM Eastern

Compare

Insmed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy

Based on 25 Analyst Ratings

Sell
1

Hold
0

Buy
24

Based on 25 Wall Street analysts who have issued ratings for Insmed in the last 12 months, the stock has a consensus rating of "Buy." Out of the 25 analysts, 1 has given a sell rating, 22 have given a buy rating, and 2 have given a strong buy rating for INSM.

Consensus Price Target

$213.23
52.71% Upside

According to the 25 analysts' twelve-month price targets for Insmed, the average price target is $213.23. The highest price target for INSM is $263.00, while the lowest price target for INSM is $135.00. The average price target represents a forecasted upside of 52.71% from the current price of $139.63.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for INSM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Insmed and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INSM Analyst Ratings Over Time

Type	Current Forecast 5/5/25 to 5/5/26	1 Month Ago 4/5/25 to 4/5/26	3 Months Ago 2/4/25 to 2/4/26	1 Year Ago 5/5/24 to 5/5/25
Strong Buy	2 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	22 Buy rating(s)	20 Buy rating(s)	19 Buy rating(s)	16 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$213.23	$212.67	$204.24	$94.00
Forecasted Upside	52.71% Upside	30.93% Upside	33.98% Upside	29.51% Upside
Consensus Rating	Buy	Buy	Buy	Buy

INSM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

INSM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Insmed Stock vs. The Competition

Type	Insmed	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.30	2.52
Consensus Rating	Buy	Hold	Moderate Buy
Predicted Upside	52.29% Upside	871.41% Upside	15.38% Upside
News Sentiment Rating	Positive News See Recent INSM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/21/2026	Weiss Ratings Not Rated		Reiterated Rating	Sell (D-)
4/17/2026	Roth Mkm 2 of 5 stars	Adam Walsh Not Rated	Reiterated Rating	Buy	$212.00	+47.55%
4/16/2026	Guggenheim 5 of 5 stars		Reiterated Rating	Buy	$230.00	+56.74%
4/14/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$212.00 ➝ $216.00	+42.91%
4/10/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$200.00	+25.32%
4/1/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$231.00 ➝ $237.00	+43.87%
3/30/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$166.00 ➝ $212.00	+45.91%
3/26/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$230.00 ➝ $245.00	+64.23%
3/25/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Graig Suvannavejh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$204.00 ➝ $206.00	+41.96%
3/24/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$210.00 ➝ $215.00	+52.87%
Get the Latest News and Ratings for INSM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.
3/24/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Willey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$205.00 ➝ $208.00	+49.42%
3/24/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Zemansky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$211.00 ➝ $213.00	+47.94%
3/23/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Benjamin Burnett Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$208.00 ➝ $175.00	+20.86%
3/16/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faisal Khurshid Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$228.00	+57.30%
1/12/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$205.00	+22.88%
1/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$223.00 ➝ $215.00	+22.72%
12/18/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$241.00	+45.42%
12/18/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
12/18/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$167.00	-15.85%
12/16/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Olivia Brayer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$216.00 ➝ $230.00	+16.80%
12/15/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrea Tan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$225.00 ➝ $258.00	+30.04%
12/4/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$263.00	+27.19%
10/1/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gavin Clark-Gartner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$180.00	+22.88%
8/20/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$111.00 ➝ $135.00	+4.70%
8/20/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Phipps Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:13 PM ET.

INSM Forecast - Frequently Asked Questions

: According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Insmed is $213.23, with a high forecast of $263.00 and a low forecast of $135.00.
: 25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There is currently 1 sell rating, 22 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
: According to analysts, Insmed's stock has a predicted upside of 52.71% based on their 12-month stock forecasts.
: Over the previous 90 days, Insmed's stock had 1 upgrade by analysts.
: Insmed has been rated by research analysts at Bank of America, Barclays, Guggenheim, HC Wainwright, Jefferies Financial Group, Leerink Partners, Mizuho, Morgan Stanley, Raymond James Financial, Roth Mkm, Royal Bank Of Canada, Stifel Nicolaus, Weiss Ratings, and Wells Fargo & Company in the past 90 days.
: Analysts like Insmed more than other "medical" companies. The consensus rating for Insmed is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how INSM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Insmed Recommendations

This page (NASDAQ:INSM) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Stock Forecast & Price Target

Insmed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

INSM Analyst Ratings Over Time

INSM Analyst Recommendations By Month

INSM Price Targets by Month

Insmed Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

INSM Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Insmed Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Stock Forecast & Price Target

Insmed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

INSM Analyst Ratings Over Time

INSM Analyst Recommendations By Month

INSM Price Targets by Month

Insmed Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

INSM Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Insmed Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools